Satellite Symposium

The Association of Biotechnology Led Enterprises and Open Health Systems Laboratory Present

Rescuing and Repurposing of Drugs for Cancer
May 9, 2014 · 3:00 – 6:00 p.m.
Bethesda North Marriott Hotel · Bethesda, Maryland U.S.A.

As the burden of cancer continues to escalate across the globe it is of paramount importance that efforts are not limited to finding novel chemical entities which require inordinate financial resources. Another approach being proposed is to “repurpose” FDA-approved drug agents. On Friday May 9, the Accelerating Anticancer Agent Development and Validation Workshop will offer a satellite symposium on Rescuing and Repurposing of Drugs for Cancer. This symposium will provide a road map from rediscovering of drug candidates to their commercialization. This is of particular importance to scientists from large pharmaceutical companies to generic houses in India. In fact, this represents a new “frontier” for business opportunity especially for the pharmaceutical industry in India. This opportunity to partner with the USFDA represents the ability to benefit Indian society by creating a bridge to highly effective examples of new drug development that is an international standard, and balances scientific and commercial prospects with the social good and needs of patients.


  • Roadmap
    Shanker Gupta, PharmD; National Cancer Institute, Pharmaceutical Development Branch
  • Opening Remarks
    H. Kim Lyerly, MD; Duke University
  • Insight into Oncogenic Pathways: An Opportunity for Drug Repurposing
    William C. Reinhold, National Cancer Institute Genetics and Bioinformatics Group
  • Case Study: Repurposing Niclosamide
    H. Kim Lyerly, MD; Duke University, and
    Vikram Gota, MD; Tata Memorial Centre/ Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
  • Case Study: Radiation Sensitizers
    Mansoor M. Ahmed, PhD; National Cancer Institute, Radiation Research Program
  • Clinical Trials Design
    Shivaani Kummar, MD; National Cancer Institute Division of Cancer Treatment and Diagnosis (DCTD)
  • Regulation and Repurposing
    Eileen E. Navarro-Almario, MD, FACP; U.S. Food and Drug Administration, Office of Computational Science, Office of Translational Science, Center for Drug Evaluation and Research, and
    Lilliam Rosario, PhD; U.S. Food and Drug Administration, Director of the Office of Computational Science
  • Intellectual Property: Looking for New Ways
    Charles Maynard and Maithili Daphtary, PhD; Open Health Systems Laboratory
  • Organization for Collaboration and Business Models for Commercialization
    Falguni Sen, PhD; Fordham University Global Healthcare Innovation Management Center (GHIM)
  • Next Steps
    Anil Srivastava, Open Health Systems Laboratory
  • Networking Reception

While there is no additional cost to attend, advance sign-up is required to attend the Symposium. Check this option in the on-line registration for the AAADV Workshop.

Sponsors of the RRDC Symposium

Association of Biotechnology Enterprises (ABLE): ABLE is a national forum that represents the Indian biotechnology sector. Launched in April 2003, the primary objective of ABLE is to accelerate the pace of growth of the biotechnology industry in India, through encouraging greater investment in the sector, providing a platform for domestic and overseas companies to explore collaborations and partnerships, partnering with the Government of India in their biotechnology endeavors and forging stronger links between academia and industry.

Open Health Systems Laboratory (OHSL): OHSL was conceived to focus on building global team science consortia by leveraging the best biomedical informatics, information and communication technology to address the key questions of medical science and to provide a quicker and better global public health response. OHSL and its strategic partners undertake projects in life sciences, which are innovative, path breaking, and proof-of-concepts requiring cross-sector collaboration. OHSL was conceived with a focus on team science, leveraging biomedical informatics and information technology for quicker and better global health response.

Comments are closed.